scholarly journals Childhood cancer incidence and survival in Thailand: A comprehensive population-based registry analysis, 1990-2011

2018 ◽  
Vol 66 (1) ◽  
pp. e27428 ◽  
Author(s):  
Serena S. Bidwell ◽  
Catherine C. Peterson ◽  
Kathryn Demanelis ◽  
Katie R. Zarins ◽  
Rafael Meza ◽  
...  
Author(s):  
Eduardo Gutiérrez-Abejón ◽  
Eduardo Tamayo ◽  
Débora Martín-García ◽  
F. Javier Álvarez ◽  
Francisco Herrera-Gómez

The first wave of the COVID-19 pandemic collapsed the hospitals in Castile and Leon (Spain). An analysis of the clinical characteristics, drug therapies and principal outcome predictors in the COVID-19 hospitalized patients from 1 March to 31 May 2020 is presented through a population-based registry study. Hospital stay variables, ventilation mode data and clinical outcomes were observed. In Castile and Leon hospitals, 7307 COVID-19 patients were admitted, with 57.05% being male and a median of 76 years. The mortality rate was 24.43%, with a high incidence of severe acute respiratory syndrome (SARS) (14.03%) and acute kidney injury (AKI) (10.87%). The most used medicines were antibiotics (90.83%), antimalarials (42.63%), steroids (44.37%) and antivirals, such as lopinavir/ritonavir (42.63%). The use of tocilizumab (9.37%) and anti-SIRS (systemic inflammatory response syndrome) medicines (7.34%) were remarkable. Fundamentally, death occurred more likely over 65 years of age (OR: 9.05). In addition, the need for ventilation was associated with a higher probability of death (OR: 3.59), SARS (OR: 5.14) and AKI (OR: 2.31). The drug-use pattern had been modified throughout the COVID-19 first wave. Multiple factors, such as age, gender and the need for mechanical ventilation, were related to the worst evolution prognosis of the disease.


2017 ◽  
Vol 187 (5) ◽  
pp. 982-991 ◽  
Author(s):  
Rebecca D Kehm ◽  
Logan G Spector ◽  
Jenny N Poynter ◽  
David M Vock ◽  
Theresa L Osypuk

2021 ◽  
Vol 8 ◽  
Author(s):  
Eduardo Gutiérrez-Abejón ◽  
Débora Martín-García ◽  
Eduardo Tamayo ◽  
F. Javier Álvarez ◽  
Francisco Herrera-Gómez

Introduction: One of the worst clinical outcomes of the coronavirus disease 2019 (COVID-19) pandemic was acute kidney injury (AKI).Methods: This manuscript presents results from a population-based registry study assessing treatment, comorbidities, and predictors of hospital death among COVID-19 patients with AKI from March 1st to May 31th, 2020. Death, oxygen delivery and ventilation, acute dialysis need, use of medications, and various clinical outcomes, in addition to the length of stay in the hospital and intensive care unit (ICU), were evaluated.Results: In Castile and Leon, the largest region of Spain, 10.87% of the patients admitted for COVID-19 (n = 7,307) developed AKI. These patients were known by having hypertension (57.93%), cardiovascular disease (48.99%), diabetes (26.7%) and chronic kidney disease (14.36%), and they used antibiotics (90.43%), antimalarials (60.45%), steroids (48.61%), antivirals (33.38%), anti-systemic inflammatory response syndrome (SIRS) drugs (9.45%), and tocilizumab (8.31%). Mortality among patients with AKI doubled that observed in patients without AKI (46.1 vs. 21.79%). Predictors of hospital death in COVID-19 patients with AKI were ventilation needs (OR = 5.9), treatment with steroids (OR = 1.7) or anti-SIRS (OR = 2.4), severe acute respiratory syndrome (SARS) occurrence (OR = 2.8), and SIRS occurrence (OR = 2.5).Conclusions: Acute kidney injury is a frequent and serious complication among COVID-19 patients, with a very high mortality, that requires more attention by treating physicians, when prescribing medications, by looking for manifestations particular to the disease, such as SARS or SIRS.


2018 ◽  
Vol 57 (11) ◽  
pp. 1547-1555 ◽  
Author(s):  
Anniina Tolkkinen ◽  
Laura Madanat-Harjuoja ◽  
Mervi Taskinen ◽  
Matti Rantanen ◽  
Nea Malila ◽  
...  

2017 ◽  
Vol 49 ◽  
pp. 202-215 ◽  
Author(s):  
Zuelma A. Contreras ◽  
Johnni Hansen ◽  
Beate Ritz ◽  
Jorn Olsen ◽  
Fei Yu ◽  
...  

2012 ◽  
Vol 28 (3) ◽  
pp. 819-827 ◽  
Author(s):  
A. Overbeek ◽  
M. H. van den Berg ◽  
C. W. P. M. Hukkelhoven ◽  
L. C. Kremer ◽  
M. M. van den Heuvel-Eibrink ◽  
...  

Author(s):  
Amr S Soliman ◽  
Saad Alshahrani MD PhD ◽  
Robert M Chamberlain PhD ◽  
Ahmed Hablas MD ◽  
Steven Remmenga MD ◽  
...  

Background: Uterine cancer is one of the common women’s cancers worldwide. There are significant variations in uterine cancer incidence rates globally and the incidence in Egypt is one of the lowest. Several studies have shown that hysterectomy might be a factor in underestimating the observed incidence of uterine cancer. However, no studies have been conducted in Egypt to examine this observation. Methods: Pathologic reports of all 1040 hysterectomy specimens examined in 2013 and 2014 in the Gharbiah province, Egypt were abstracted. Prevalence of hysterectomy was estimated and used for adjusting the incidence rate of uterine cancer in the Gharbiah population-based registry by excluding the hysterectomized women from the population at risk. Pre- and post- adjustment rates were compared and 95% confidence intervals (CIs) were calculated. Results: The prevalence of hysterectomy was estimated as 13.1 per 10,000 women, 95% CI (12.65-13.66). The prevalence of hysterectomy did not have a significant impact on uterine cancer incidence [pre-adjustment (2.78, 95% CI 2.58-3.00) and post-adjustment (2.79, 95% CI 2.58-3.00)]. Observing a significant effect of hysterectomy on underestimating the incidence of uterine cancer in this population required multiplying the observed prevalence by at least 110 times. Discussion: This study confirmed the previously documented low incidence of uterine cancer in this population of Egypt. The lack of evidence about the possible role of hysterectomy in lowering uterine cancer incidence justifies the need for additional research to identify the protective factors for uterine cancer in this population.


Sign in / Sign up

Export Citation Format

Share Document